Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2000–2018

Grant, Gavin B.; Desai, Shalini; Dumolard, Laure; Kretsinger, Katrina; Reef, Susan E.

doi:10.15585/mmwr.mm6839a5

Cited by 52 publications

(38 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the purposes of this study, international surveillance networks focusing on a specific outcome were not taken into consideration, such as the WHO initiative for surveillance of rubella and congenital rubella syndrome, 27 nor did it take into consideration networks that did not extend beyond the boundaries of a country, such as the National Birth Defects Prevention Network (NBDPN) in the United States. 28,29 Another initiative that was not used in our analyses, but which is worthy of mention is the International Union for Circumpolar Health Birth Defect Working Group (IUCH-BDWG), which has catalogued surveillance systems in existence and which are being developed in the more northerly regions of the world.…”

Section: Discussionmentioning

confidence: 99%

Redes internacionais de colaboração para a vigilância das anomalias congênitas: uma revisão narrativa

Cardoso-dos-Santos

Magalhães

Medeiros-de-Souza

et al. 2020

Epidemiologia e Serviços de Saúde

View full text Add to dashboard Cite

Objective: to identify international congenital anomaly surveillance collaboration networks, to list the programs that compose them and to compare their main characteristics. Methods: this was a narrative literature review by means of a MEDLINE database search (via PubMed) and searches involving websites, reports and official documents. Results: six international congenital anomaly surveillance collaboration networks were identified (ECLAMC, ICBDSR, EUROCAT, BINOCAR, SEAR-NBBD and ReLAMC), comprised of 98 programs present in 58 different countries on all continents, except Africa; the main characteristics regarding type of surveillance, coverage and location were discussed in a comparative manner. Conclusion: international collaborative networks are important players for congenital anomaly surveillance, contributing to the understanding of the global epidemiological scenario of these conditions, in addition to acting both to strengthen individual existing programs and also to create surveillance initiatives in unassisted regions.

show abstract

Section: Discussionmentioning

confidence: 99%

Redes internacionais de colaboração para a vigilância das anomalias congênitas: uma revisão narrativa

Cardoso-dos-Santos

Magalhães

Medeiros-de-Souza

et al. 2020

Epidemiologia e Serviços de Saúde

View full text Add to dashboard Cite

show abstract

“…A consensus view will have to await vaccine studies in pregnant NHPs, with the a hope being that a vaccine that is able to reduce substantially ZIKV replication will largely prevent or significantly ameliorate the rate and severity of CZS. Such a hope is supported by the success of vaccination campaigns against rubella 37 (family Matonaviridae, genus Rubivirus) and bovine viral diarrhoea virus (family Flaviviridae, genus Pestivirus) 38 .…”

Section: Discussionmentioning

confidence: 99%

The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates

et al. 2020

View full text Add to dashboard Cite

The Sementis Copenhagen Vector (SCV) is a new vaccinia virus-derived, multiplication-defective, vaccine technology assessed herein in non-human primates. Indian rhesus macaques (Macaca mulatta) were vaccinated with a multi-pathogen recombinant SCV vaccine encoding the structural polyproteins of both Zika virus (ZIKV) and chikungunya virus (CHIKV). After one vaccination, neutralising antibody responses to ZIKV and four strains of CHIKV, representative of distinct viral genotypes, were generated. A second vaccination resulted in significant boosting of neutralising antibody responses to ZIKV and CHIKV. Following challenge with ZIKV, SCV-ZIKA/CHIK-vaccinated animals showed significant reductions in viremias compared with animals that had received a control SCV vaccine. Two SCV vaccinations also generated neutralising and IgG ELISA antibody responses to vaccinia virus. These results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens.

show abstract

“…For more than a millennium, the measles virus caused human devastation and death, infecting nearly everyone [ 1 ]. Measles and rubella are vaccine-preventable and eradicable diseases; however, measles remains one of the leading causes of childhood morbidity and mortality, and rubella is the leading cause of vaccine-preventable birth defects [ 2 • , 3 • ]. Measles virus infection causes severe viremia and lymphopenia; common measles complications in children include otitis media, pneumonia, and diarrhea.…”

Section: Introductionmentioning

confidence: 99%

“…Measles virus infection also causes immunosuppression that can last for months to years, diminishing preexisting antibodies against other pathogens [ 1 , 10 , 11 , 12 , 13 , 14 ]. Rubella virus infection generally causes a mild illness; however, when the infection occurs during pregnancy, especially in the first trimester, miscarriage, fetal death, stillbirth, or a constellation of birth defects known as congenital rubella syndrome (CRS) can occur [ 2 • ].…”

Section: Introductionmentioning

confidence: 99%

A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination

Prausnitz

Goodson

Rota

et al. 2020

Current Opinion in Virology

View full text Add to dashboard Cite

While morbidity and mortality associated with measles and rubella (MR) have dramatically decreased, there are still >100 000 estimated deaths due to measles and an estimated 100 000 infants born with congenital rubella syndrome annually. Given highly effective MR vaccines, the primary barrier to global elimination of these diseases is low vaccination coverage, especially among the most underserved populations in resource-limited settings. In contrast to conventional MR vaccination by hypodermic injection, microneedle patches are being developed to enable MR vaccination by minimally trained personnel. Simplified supply chain, reduced need for cold chain storage, elimination of vaccine reconstitution, no sharps waste, reduced vaccine wastage, and reduced total system cost of vaccination are advantages of this approach. Preclinical work to develop a MR vaccine patch has proceeded through successful immunization studies in rodents and non-human primates. On-going programs seek to make MR vaccine patches available to support MR elimination efforts around the world.

show abstract

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2000–2018

Cited by 52 publications

References 4 publications

Redes internacionais de colaboração para a vigilância das anomalias congênitas: uma revisão narrativa

Redes internacionais de colaboração para a vigilância das anomalias congênitas: uma revisão narrativa

The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates

A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination

Contact Info

Product

Resources

About